4.7 Article

Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein

Journal

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 14, Issue 12, Pages E1060-E1066

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2010.07.003

Keywords

Serological responses; Pneumocystis; Major surface glycoprotein (Msg); Children

Funding

  1. Medical Research Service, Department of Veterans Affairs NIH [R01AI-06492, R01 HL-090335]
  2. The Elizabeth Glaser Pediatric AIDS Foundation [PG 51153-26]
  3. Fondo Nacional de Desarrollo Cientifico y Tecnologico, Santiago, Chile (FONDECYT) [1060750]

Ask authors/readers for more resources

Objectives: To characterize the seroepidemiological features of Pneumocystis jirovecii infection in healthy Chilean children using overlapping fragments (A, B, C) of the P. jirovecii major surface glycoprotein (Msg). Methods: Serum antibodies to MsgA, MsgB, and MsgC were measured every 2 months by enzyme-linked immunosorbent assay (ELISA) in 45 Chilean infants from about age 2 months to 2 years. Results: Peak antibody levels (usually reached at age 6 months) and the force (or rate) of infection were somewhat greater for MsgC than for MsgA. Significant seasonal variation in antibody levels was only found with MsgA. Respiratory infections occurred in most children, but nasopharyngeal aspirates were of limited value in detecting the organism. In contrast, serological responses commonly occurred, and higher levels only to MsgC were significantly related to the number of infections. Conclusions: Serological responses to recombinant Msg fragments provide new insights into the epidemiological and clinical features of P. jirovecii infection of early childhood. MsgA, the amino terminus fragment, is more sensitive in detecting seasonal influences on antibody levels, whereas MsgC is better able to detect changes in antibody levels in response to clinical infection. (C) 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available